Top Suppliers:I want be here


140651-18-9

140651-18-9 structure
140651-18-9 structure
  • Name: CAY10574
  • Chemical Name: 4-[(3,5-diamino-1H-pyrazol-4-yl)hydrazinylidene]cyclohexa-2,5-dien-1-one
  • CAS Number: 140651-18-9
  • Molecular Formula: C9H10N6O
  • Molecular Weight: 218.215
  • Catalog: Signaling Pathways Cell Cycle/DNA Damage CDK
  • Create Date: 2016-07-16 20:22:47
  • Modify Date: 2025-09-18 12:57:09
  • CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC50 of 0.35 μM. CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity[1][2].

Name 4-[(3,5-diamino-1H-pyrazol-4-yl)hydrazinylidene]cyclohexa-2,5-dien-1-one
Synonyms 3tn8
2clx
Cdk9 Inhibitor II
Phenol, 4-[(E)-2-(3,5-diamino-1H-pyrazol-4-yl)diazenyl]-
4-[(E)-(3,5-Diamino-1H-pyrazol-4-yl)diazenyl]phenol
F18
CAN-508
Description CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC50 of 0.35 μM. CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity[1][2].
Related Catalog
Target

CDK9/cyclinT1:0.35 μM (IC50)

CDK2/cyclinE:20 μM (IC50)

cdk2/cyclin A:69 μM (IC50)

Cdk4/cyclin D1:13.5 μM (IC50)

CDK7/cyclin H:26 μM (IC50)

Cdk1/cyclin B:44 μM (IC50)

In Vitro CAN508 reduces the frequency of S-phase cells of the cancer cell line HT-29 in antiproliferation assays[1]. CAN508 (20-40 μM; 72 hours) significantly reduces cell proliferation in a dose dependent manner in all three esophageal adenocarcinoma cell lines (SKGT4, OE33 and FLO-1 cells) with IC50s ranging from 34.99 to 91.09 μM[2]. CAN508 (40 μM; 72 hours) increases apoptosis in all three esophageal adenocarcinoma cells[2]. Apoptosis Analysis[1] Cell Line: SKGT4, OE33 and FLO-1 cells Concentration: 40 μM Incubation Time: 72 hours Result: Increased apoptosis by 2 fold in all three esophageal adenocarcinoma cells compared to untreated controls.
In Vivo CAN508 (60 mg/kg; i.p.; daily for 10 days) has antitumor effects in esophageal adenocarcinoma xenografts[1]. Animal Model: 4 weeks-old female nude mice (esophageal adenocarcinoma xenografts)[1] Dosage: 60 mg/kg Administration: I.p.; daily for 10 days Result: Caused reduction of tumor growth starting from post-treatment day three with 50.83% reduction.
References

[1]. Krystof V, et al. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006;49(22):6500-6509.

[2]. Tong Z, et al. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget. 2017;8(17):28696-28710.

Density 1.7±0.1 g/cm3
Boiling Point 638.3±55.0 °C at 760 mmHg
Molecular Formula C9H10N6O
Molecular Weight 218.215
Flash Point 339.8±31.5 °C
Exact Mass 218.091614
PSA 125.67000
LogP 0.40
Vapour Pressure 0.0±2.0 mmHg at 25°C
Index of Refraction 1.803
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.